This edition of the HDYO Research Video Series, we look at the article, SURVEYOR opens the door for drugs that treat cognition. Sage Therapeutics announced results from SURVEYOR, a trial that looked at cognitive changes in people with HD, and tested short-term safety of dalzanemdor. The study was small but met key goals, and additional trials are in progress.
The HDYO Research Video Series is sponsored by Roche, Sage Therapeutics, Teva Pharmaceutical, uniQure, Wave Life Sciences, Griffin Foundation and Neurocrine Biosciences.